Before and after endoscopic images of B-UP (Cohort
Post# of 72430
![Avatar](/images/ProfileImages/398685088_3064_306524.png)
![csvexB-UP_POC.jpg](https://investorshub.advfn.com/uimage/uploads/2018/2/19/csvexB-UP_POC.jpg)
B-UP Topline Results
Rate of Clinical Remission (% of patients achieving)
- 60% Cohort A (3 of 5 patients)
- 67% Cohort B (4 of 6 patients)
- 75% Cohort C (3 of 4 patients)
(i) #Endoscopy subscore ≤ 1 (% of patients achieving)
- 80% Cohort A (4 of 5 patients)
- 67% Cohort B (4 of 6 patients)
- 75% Cohort C (3 of 4 patients)
(ii) Rectal Bleeding subscore of 0 (% of patients achieving)
- 80% Cohort A (4 of 5 patients)
- 100% Cohort B (6 of 6 patients)
- 100% Cohort C (4 of 4 patients)
(iii) Stool Frequency subscore, improvement or no change from baseline (% of patients achieving)
- 100% Cohort A (5 of 5 patients)
- 100% Cohort B (6 of 6 patients)
- 100% Cohort C (4 of 4 patients)
http://www.ipharminc.com/press-release/2017/7...brilacidin
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)